Novo Nordisk (NVO) earnings
Novo Nordisk (NVO) reported net income of DKK 102.43B in fiscal 2025 (the year ended December 31, 2025). That is 1.4% higher than the DKK 100.99B of fiscal 2024. Figures as of 18 Nov 2026, 06:56 UTC, from Yahoo Finance.
Key facts
- Earnings (net income), fiscal 2025
- DKK 102.43B
- Change on fiscal 2024
- +1.4%
- Highest on record
- DKK 102.43Bfiscal 2025
- Lowest on record
- DKK 55.53Bfiscal 2022
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in DKK. Figures, not advice.
Novo Nordisk earnings, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was DKK 102.43B in fiscal 2025 and the lowest DKK 55.53B in fiscal 2022.
Earnings (net income) by fiscal year
Novo Nordisk earnings, year by year
| Fiscal year | Earnings (net income) | Change | Year ended |
|---|---|---|---|
| 2025 | DKK 102.43B | 1.4% up | |
| 2024 | DKK 100.99B | 20.7% up | |
| 2023 | DKK 83.68B | 50.7% up | |
| 2022 | DKK 55.53B | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
How to read it
Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.
Earnings (net income) at health care companies of similar size
| Company | Earnings (net income) | Fiscal year |
|---|---|---|
| Gilead Sciences GILD | $8.51B | 2025 |
| Abbott Laboratories ABT | $6.52B | 2025 |
| Novo Nordisk NVO | DKK 102.43B | 2025 |
| Pfizer PFE | $7.77B | 2025 |
| Danaher DHR | $3.61B | 2025 |
| Intuitive Surgical ISRG | $2.86B | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Novo Nordisk, figure by figure
- Novo Nordisk market cap
- Novo Nordisk revenue
- Novo Nordisk earnings per share (EPS)
- Novo Nordisk P/E ratio
- Novo Nordisk P/S ratio
- Novo Nordisk P/B ratio
- Novo Nordisk free cash flow
- Novo Nordisk operating margin
- Novo Nordisk dividend
- Novo Nordisk shares outstanding
- Novo Nordisk total debt
- Novo Nordisk cash on hand
- Novo Nordisk total assets
- Novo Nordisk return on equity (ROE)
- Novo Nordisk return on invested capital (ROIC)
Novo Nordisk (NVO) overview: price, valuation and scorecardAll health care companies by market value
Novo Nordisk earnings: questions and answers
What is Novo Nordisk's net income?
Novo Nordisk (NVO) reported net income of DKK 102.43B in fiscal 2025 (the year ended December 31, 2025). That is 1.4% higher than the DKK 100.99B of fiscal 2024.
What are the highest and lowest net income figures on record for Novo Nordisk?
Across the 4 fiscal years on record (2022–2025), the highest was DKK 102.43B in fiscal 2025 and the lowest DKK 55.53B in fiscal 2022.
How is Novo Nordisk's net income calculated?
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
Fiscal years are named for the calendar year they end in.
Learn: earnings
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Novo Nordisk (NVO) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/NVO/earnings
Underlying data: Yahoo Finance.